美托洛尔缓释片联合曲美他嗪治疗冠心病心力衰竭的临床观察  

Clinical Observation of Metoprolol Combined with Trimetazidine in the Treatment of Coronary Heart Disease and Heart Failure

作　　者：王仁荣[1] 杨承健[1] 徐欣[1] 陈浩[1] WANG Ren-rong;YANG Cheng-jian;XU Xin;CHEN Hao(Department of Cardiology,Wuxi Second People's Hospital,Wuxi,Jiangsu Province,214000 China)

机构地区：[1]无锡市第二人民医院心血管内科

出　　处：《世界复合医学》2019年第11期178-180,共3页World Journal of Complex Medicine

摘　　要：目的论述冠心病心力衰竭采取曲美他嗪、美托洛尔缓释片联合治疗的应用效果。方法该次选择2015年1月-2016年12月于该院接受治疗的冠心病心力衰竭患者140例作为观察目标,随机将其分为观察组与对照组,单纯以美托洛尔缓释片药物治疗对照组患者,以美托洛尔缓释片、曲美他嗪联合治疗观察组患者,比较两组总有效率,评估各组患者治疗前后心功能相关指标差异。对患者随访3年,计算3年内患者死亡概率。结果观察组患者该次治疗总有效率(98.57%)明显高于对照组85.71%(χ~2=7.99,P<0.05)。两组患者未用药治疗前各项心功能指标差异无统计学意义,经治疗后,观察组患者LVESD(32.94±1.78)mm、LVEDD(51.95±1.88)mm、HR(71.14±2.24)次/min均明显低于对照组,LVEF(53.18±2.02)%较对照组(43.15±2.01)%相比更高(P<0.05)。观察组患者3年内死亡率(4.28%)均明显低于对照组21.43%(χ~2=9.18,P<0.05)。结论冠心病心力衰竭以曲美他嗪、美托洛尔缓释片双药联合治疗效果更佳,能够改善患者心功能指标,提高患者3年内生存率,值得应用推广。Objective To discuss the application effect of trimetazidine and metoprolol in the treatment of coronary heart disease and heart failure. Methods The choice in this study, 140 patients with coronary heart disease and heart failure treated in the hospital from January 2015 to December 2016 were selected as the observation objectives. According to the results of the lottery, they were ran-domly divided into observation group and control group. Patients in control group were treated with metoprolol alone, and patients in observation group were treated with metoprolol and trimetazidine. The total number of patients in the two groups was compared. Effi-ciency, evaluation of patients before and after treatment cardiac function related indicators differences. The patients were followed up for three years and the mortality rate was calculated within three years. Results The total effective rate of the treatment group(98.57%) was significantly higher than that of the control group85.71%(χ~2=7.99, P<0.05). There was no significant difference in the scores of cardiac function between the two groups before treatment. After treatment, the patients in the observation group were LVESD(32.94±1.78) mm, LVEDD(51.95±1.88) mm, and HR(71.14±2.24) times/min was significantly lower than the control group, LVEF(53.18±2.02)% was higher than the control group(43.15±2.01)%(P<0.05). The mortality rate(4.28%) in the observation group was significantly lower than that in the control group by 21.43%(χ~2=9.18, P <0.05). Conclusion Trimetazidine combined with metoprolol is more effective in treating CHF. It can improve the cardiac function index and the survival rate of patients within 3 years. It is worth popularizing.

关 键 词：美托洛尔缓释片 曲美他嗪 冠心病 心力衰竭 

分 类 号：R453[医药卫生—治疗学]